View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 23, 2021updated 07 Jan 2022 8:54am

FDA grants 510(k) clearance for Sight Sciences’ TearCare System

TearCare comprises SmartHub, a reusable hardware controller, and SmartLids, a software-controlled eyelid technology.

The US Food and Drug Administration (FDA) has granted 510(k) clearance for Sight Sciences’ TearCare System to treat meibomian gland dysfunction (MGD), which causes dry eye disease (DED).

The regulatory approval allows the TearCare System to provide localised heat therapy in adults when used in conjunction with the manual meibomian glands expression.

This therapy will be provided for adult patients with evaporative DED caused due to MGD.

The system provides localised heat therapy to help soften or liquify thickened meibum to enable effective gland clearance.

It comprises SmartHub, a reusable hardware controller, as well as SmartLids, a software-controlled eyelid technology.

The SmartLids are applied to the outer surface of the eyelids to fit to provide heat therapy within a tight therapeutic temperature window to the inner eyelid.

The portable SmartHub system offers sensor-driven feedback for the management of SmartLids’ heat.

Sight Sciences co-founder and CEO Paul Badawi said: “The entire Sight Sciences community is committed to advancing treatment for MGD patients and expanding much needed patient access to insured treatment.

“MGD is the leading cause of DED and can present serious complications for patients if left untreated, yet both the understanding and treatment of MGD as the underlying cause of dry eye is still evolving.

“We remain dedicated to bringing an insurance recognised treatment option to the millions of underserved patients living with MGD.”

The approval was based on the data obtained from several studies, including the pivotal OLYMPIA study.

The company plans to continue the research support for the TearCare System’s future indications to provide additional clinical data that could potentially support insurance coverage for the procedure.

In 2019, Sight Sciences commenced patient enrolment for the Gemini clinical trial to evaluate safety and efficacy of the OMNI Surgical System.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network